SOURCE: Health Enhancement Products, Inc.

November 06, 2007 08:30 ET

Health Enhancement Products Reports Results in the Second Testing of the ProAlgaZyme Clinical Lot Used in the Suspended Clinical Trial

Second Test Also Confirmed That the Clinical Materials That Had Partially Frozen Showed Loss of Active Components, Compared to the Original Product

SCOTTSDALE, AZ--(Marketwire - November 6, 2007) - Health Enhancement Products, Inc. (OTCBB: HEPI) announced today that they have received the second, independent test results of the clinical lot of ProAlgaZyme that was used in the recently suspended clinical trial. This test was designed to detect potential degradation of the active protein components in ProAlgaZyme. Dr. Michael Tempesta, Chairman of the Scientific Advisory Board stated: This second round of tests further confirms our belief that the key protein-based components of ProAlgaZyme are sensitive to freezing, and that the original clinical ProAlgaZyme product lot was degraded during shipment to Minnesota during last winter. As stated in our earlier announcement, all bottles will now be marked "Do not Freeze."

About Health Enhancement Products, Inc. and ProAlgaZyme

Health Enhancement Products Inc. is a nutraceutical company engaged in the development of a Dietary Supplement product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme. HEPI Pharmaceuticals, Inc. is exploring the development of the potential pharmaceutical applications of ProAlgaZyme.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, our inability to obtain regulatory approvals necessary to market and sell PAZ as a pharmaceutical, and the company's ability to secure funding, including for the subsidiary's pharmaceutical development of PAZ. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit

Contact Information

  • Contact information:
    John Gorman
    Email Contact: Email Contact